ReviewFrontiers in transplantation2024
BK polyomavirus infection: more than 50 years and still a threat to kidney transplant recipients.
Review in Frontiers in transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- BKV activates the interferon-β response in primary and immortalized microvascular endothelial cells late in the infectious cycle, resulting in persistence.Journal of virology · 2026Article
- Article
- BKPyV-Co-Architect of the Fate of a Renal Transplant During a One-Year Observation Period.International journal of molecular sciences · 2026Article
- Remodeling of the cellular membrane architecture in response to BK polyomavirus infection.Virology journal · 2026Review
- Human bocavirus 1 viremia-associated pediatric sepsis with a triphasic urinary course: a case report.Translational pediatrics · 2026Article
- Development of a conceptual model of BKV impacts on health-related quality of life in kidney transplant recipients: a qualitative study.Journal of patient-reported outcomes · 2026Article
- BK Polyomavirus-Associated Nephropathy Complicated by Life-Threatening Hemorrhagic Pericardial Effusion Following Immunosuppression Reduction in a Kidney Transplant Recipient: A Case Report.Case reports in transplantation · 2026Article
- Non-human leukocyte antigen antibodies in kidney transplantation: pathogenic mechanisms, detection methods, and clinical implications.Clinical transplantation and research · 2025Review
- Immune Modulation by Microbiota and Its Possible Impact on Polyomavirus Infection.Pathogens (Basel, Switzerland) · 2025Review
- A Phase I Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against BK-Virus in Adult Kidney Transplant Recipients.Journal of medical virology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BK polyomavirus (BKPyV) is a ubiquitous human polyomavirus and a major infection after kidney transplantation, primarily due to immunosuppression. BKPyV reactivation can manifest as viruria in 30%-40%, viremia in 10%-20%, and BK polyomavirus-associated nephropathy (BKPyVAN) in 1%-10% of recipients. BKPyVAN is an important cause of kidney graft failure. Although the first case of BKPyV was identified in 1971, progress in its management has been limited. Specifically, there is no safe and effective antiviral agent or vaccine to treat or prevent the infection. Even in the current era, the mainstay approach to BKPyV is a reduction in immunosuppression, which is also limited by safety (risk of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.